MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
Milestone Scientific Income Statement 2011-2025 | MLSS
Annual Income Statement Milestone Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
69.4 M | 45.1 M | 65 M | 88.8 M | 178 M | 80.5 M | 14.1 M | 32.4 M | 33.7 M | 36.6 M | 54.6 M | 25.7 M | 20.1 M | 7.59 M |
Shares |
79.8 M | 72.8 M | 70.6 M | 68.8 M | 63.1 M | 45.7 M | 35.3 M | 32.7 M | 27 M | 21.4 M | 20.1 M | 17.1 M | 16.1 M | 15.2 M |
Historical Prices |
0.87 | 0.62 | 0.92 | 1.29 | 2.82 | 1.74 | 0.4 | 0.95 | 1.2 | 1.71 | 2.72 | 1.5 | 1.2 | 0.41 |
Net Income |
-4.71 M | -6.93 M | -8.71 M | -6.82 M | -7.39 M | -7.52 M | -7.43 M | -5.19 M | -5.95 M | -5.47 M | -1.7 M | 1.46 M | -870 K | -1.48 M |
Revenue |
8.63 M | 9.83 M | 8.81 M | 10.3 M | 5.44 M | 8.37 M | 9.62 M | 11.3 M | 10.5 M | 9.49 M | 10.3 M | 10 M | 8.65 M | 8.38 M |
Cost of Revenue |
2.2 M | 3.03 M | 3.91 M | 3.99 M | 1.82 M | 2.66 M | 5.19 M | 4.31 M | - | - | - | - | - | - |
Gross Profit |
6.43 M | 6.79 M | 4.9 M | 6.31 M | 3.62 M | 5.72 M | 4.43 M | 6.97 M | 6.31 M | 6.44 M | 6.7 M | 6.81 M | 5.59 M | 5.36 M |
Operating Income |
-6.76 M | -7.11 M | -8.83 M | -7.38 M | -7.45 M | -4 M | -8 M | -5.23 M | -6.51 M | -3.06 M | -790 K | 1.09 M | -520 K | -1.22 M |
Interest Expense |
60.3 K | 126 K | 54.6 K | -16.4 K | -24.8 K | -10.4 K | -7.23 K | -4.93 K | -5.09 K | -5.35 K | 2.67 K | 70.8 K | 176 K | 132 K |
EBITDA |
-6.72 M | -7.04 M | -8.76 M | -7.3 M | -7.41 M | -3.74 M | -5.58 M | -4.66 M | -6.35 M | -2.96 M | -694 K | 1.18 M | -425 K | -1.12 M |
Operating Expenses |
13.2 M | 13.9 M | 13.7 M | 13.7 M | 11.1 M | 9.72 M | 10.9 M | 12.2 M | 12.8 M | 9.5 M | 7.49 M | 5.73 M | 6.11 M | 6.59 M |
General and Administrative Expenses |
12.3 M | 13.1 M | 12.5 M | 12.7 M | 10.8 M | 9.53 M | 10.6 M | 11.9 M | 11.5 M | 9.4 M | 7.4 M | 5.53 M | 5.93 M | 6.45 M |
All numbers in USD currency
Quarterly Income Statement Milestone Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
82.3 M | 82 M | 81.9 M | 78 M | 80 M | 80 M | 79.7 M | 75.8 M | 73.7 M | 72.3 M | 72.1 M | 69.3 M | 71 M | 70.4 M | 69 M | 68.1 M | 69.6 M | 69.2 M | 66.6 M | 64.1 M | 65.8 M | 56.7 M | 49.7 M | 49.4 M | 47.7 M | 45.4 M | 40.5 M | 33.8 M | 35.6 M | 35.3 M | 34.8 M | 33.2 M | 33.6 M | 32.4 M | 32 M | 30.4 M | 29.2 M | 26 M | 22.6 M | 21.7 M | 21.4 M | 22.4 M | 21.9 M | 21.4 M | 21.2 M | 20.2 M | 17.8 M | 17.7 M | 17.3 M | 16.7 M | 16.4 M | 16.5 M | 16.2 M | 16 M | 15.3 M | 15.5 M | 15.1 M | 15 M | 15.5 M |
Net Income |
-1.15 M | -1.48 M | -1.99 M | - | -1.46 M | 224 K | -1.44 M | - | -1.47 M | -2.22 M | -1.31 M | - | -1.97 M | -2.86 M | -1.92 M | - | -2.04 M | -2.7 M | -986 K | - | -1.49 M | -3.17 M | -1.6 M | - | -2.84 M | -1.04 M | -783 K | - | -4.39 M | -1.34 M | -1.87 M | - | -1.41 M | -1.48 M | -505 K | - | -1.7 M | -1.59 M | -750 K | - | -1.57 M | -2.07 M | -419 K | - | -358 K | -169 K | 195 K | - | 1.46 M | 74 K | 151 K | - | 15.2 K | -165 K | -355 K | - | -637 K | -298 K | -142 K |
Revenue |
2.36 M | 2.32 M | 2.23 M | - | 2.51 M | 1.85 M | 2.25 M | - | 2.06 M | 2.91 M | 2.6 M | - | 2.22 M | 1.65 M | 2.7 M | - | -69.9 K | -95.9 K | 1.3 K | - | - | - | 1.81 M | - | 49.1 K | 58.7 K | 9.56 K | - | 259 K | 78.6 K | 36.8 K | - | 2.85 M | 15.5 K | -44.4 K | - | -253 K | -57.9 K | -270 K | - | -711 K | -690 K | -358 K | - | -224 K | -213 K | 2.62 M | - | -212 K | -47.1 K | 2.49 M | - | - | -46.1 K | -78.1 K | - | -60 K | - | - |
Cost of Revenue |
719 K | 706 K | 585 K | - | 678 K | 443 K | 573 K | - | 556 K | 1.02 M | 708 K | - | 763 K | 968 K | 1.02 M | - | 748 K | 1.06 M | 1.12 M | - | 410 K | 55.6 K | 527 K | - | 524 K | 752 K | 619 K | - | 1.74 M | 1.02 M | 563 K | - | 1.04 M | 874 K | 1.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
1.64 M | 1.62 M | 1.65 M | - | 1.84 M | 1.41 M | 1.68 M | - | 1.5 M | 1.89 M | 1.89 M | - | 1.45 M | 681 K | 1.68 M | - | 1.36 M | 1.37 M | 1.8 M | - | 836 K | 112 K | 1.28 M | - | 1.38 M | 1.51 M | 1.3 M | - | -120 K | 1.41 M | 1.24 M | - | 1.81 M | 1.65 M | 2.29 M | - | 1.67 M | 1.58 M | 2.2 M | - | 1.67 M | 1.2 M | 1.84 M | - | 1.71 M | 1.59 M | 1.74 M | - | 1.77 M | 1.53 M | 1.68 M | - | 1.5 M | 1.47 M | 1.26 M | - | 1.15 M | 1.6 M | 1.55 M |
Operating Income |
-1.13 M | -1.48 M | -2 M | - | -1.47 M | -1.78 M | -1.47 M | - | -1.51 M | -2.28 M | -1.34 M | - | -2.01 M | -2.88 M | -1.91 M | - | -1.98 M | -2.87 M | -984 K | - | -1.48 M | -3.17 M | -1.61 M | - | -947 K | -1.11 M | -818 K | - | -4.55 M | -1.42 M | -2 M | - | -1.41 M | -1.55 M | -526 K | - | -1.57 M | -2.02 M | -943 K | - | -835 K | -1.41 M | -71.1 K | - | -162 K | 47.5 K | 329 K | - | 436 K | 1.46 M | 168 K | - | 51.6 K | -53.6 K | -233 K | - | -540 K | -262 K | -122 K |
Interest Expense |
- | 1.52 K | 3.27 K | - | 8.01 K | 21 K | 24.5 K | - | 30.6 K | 48.7 K | 23.3 K | - | 28 K | 3.55 K | -4.74 K | - | -4.61 K | -4.46 K | -2.54 K | - | -569 | -4.06 K | -4.21 K | - | -2.63 K | -2.56 K | -2.26 K | - | -1.78 K | -1.76 K | -1.7 K | - | -1.05 K | -1.02 K | -1.21 K | - | 846 | -1 K | 1.24 K | - | 1.04 K | - | 1.21 K | - | - | - | -475 | - | 5.55 K | 30 K | 34.6 K | - | 36.5 K | 63.3 K | 42.4 K | - | 35.6 K | 34.7 K | 19.4 K |
EBITDA |
-1.11 M | -1.47 M | -1.98 M | - | -1.46 M | -1.77 M | -1.45 M | - | -1.49 M | -2.26 M | -1.33 M | - | -2 M | -2.87 M | -1.9 M | - | -1.96 M | -2.86 M | -963 K | - | -1.46 M | -3.15 M | -1.57 M | - | -921 K | -1.08 M | -792 K | - | -4.2 M | -1.18 M | -1.74 M | - | -1.25 M | -1.52 M | -491 K | - | -1.5 M | -1.97 M | -921 K | - | -815 K | -1.4 M | -65.4 K | - | -150 K | 54.5 K | 333 K | - | 449 K | 1.47 M | 172 K | - | 66.1 K | -43.6 K | -228 K | - | -524 K | -251 K | -116 K |
Operating Expenses |
2.78 M | 3.1 M | 3.65 M | - | 3.31 M | 3.19 M | 3.14 M | - | 3.01 M | 4.17 M | 3.23 M | - | 3.47 M | 3.57 M | 3.6 M | - | 3.34 M | 4.24 M | 2.79 M | - | 2.31 M | 3.28 M | 2.89 M | - | 2.32 M | 2.61 M | 2.12 M | - | 4.43 M | 2.83 M | 3.24 M | - | 3.22 M | 3.2 M | 2.81 M | - | 3.24 M | 3.6 M | 3.14 M | - | 2.5 M | 2.61 M | 1.91 M | - | 1.87 M | 1.55 M | 1.41 M | - | 1.33 M | 1.38 M | 1.51 M | - | 1.45 M | 1.53 M | 1.49 M | - | 1.69 M | 1.86 M | 1.67 M |
General and Administrative Expenses |
2.74 M | 3.03 M | 3.26 M | - | 3.06 M | 2.87 M | 3.04 M | - | 2.82 M | 3.94 M | 3.07 M | - | 3.28 M | 3.28 M | 3.12 M | - | 2.97 M | 4.01 M | 2.75 M | - | 2.28 M | 3.16 M | 2.75 M | - | 2.31 M | 2.52 M | 2.11 M | - | 2.89 M | 2.82 M | 3.02 M | - | 3.21 M | 3.08 M | 2.71 M | - | 2.93 M | 3.29 M | 3 M | - | 2.48 M | 2.59 M | 1.9 M | - | 1.84 M | 1.52 M | 1.39 M | - | 1.32 M | 1.34 M | 1.39 M | - | 1.39 M | 1.49 M | 1.45 M | - | 1.7 M | 1.8 M | 1.62 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Milestone Scientific (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Baxter International
BAX
|
$ 18.99 | 0.48 % | $ 9.68 B |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 200.87 | 0.22 % | $ 57.8 B | USA |
 |
BioLife Solutions
BLFS
|
$ 24.43 | -1.81 % | $ 1.13 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 4.79 | 2.35 % | $ 96.6 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.59 | -0.13 % | $ 2.36 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
$ 78.74 | -0.03 % | $ 40.4 B |  Schweiz |
 |
iRhythm Technologies
IRTC
|
$ 170.09 | 0.58 % | $ 5.31 B | USA |
 |
AtriCure
ATRC
|
$ 42.08 | 1.62 % | $ 1.98 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
electroCore
ECOR
|
$ 4.81 | -0.21 % | $ 26.5 K | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.76 | 1.78 % | $ 32.2 M | USA |
 |
AngioDynamics
ANGO
|
$ 13.12 | -2.42 % | $ 536 M | USA |
 |
The Cooper Companies
COO
|
$ 81.82 | -0.36 % | $ 16.3 B | USA |
 |
ICU Medical
ICUI
|
$ 147.72 | 0.34 % | $ 3.6 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 109.57 | 0.31 % | $ 5.31 B | USA |
 |
Haemonetics Corporation
HAE
|
$ 83.2 | -1.49 % | $ 4.19 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.24 | 0.33 % | $ 191 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Repro Med Systems
KRMD
|
$ 5.75 | -1.88 % | $ 262 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 83.51 | 0.18 % | $ 1.87 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 541.3 | -1.11 % | $ 192 B | USA |
 |
Masimo Corporation
MASI
|
$ 138.1 | -2.25 % | $ 7.36 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 86.52 | -0.01 % | $ 5.04 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.43 | 2.21 % | $ 24.8 M |  Israel |
 |
Nephros
NEPH
|
$ 5.08 | 2.24 % | $ 52.8 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
ResMed
RMD
|
$ 250.7 | -0.67 % | $ 36.6 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 21.79 | -1.58 % | $ 3.75 B | USA |
 |
OraSure Technologies
OSUR
|
$ 2.52 | -2.14 % | $ 188 M | USA |
 |
Pro-Dex
PDEX
|
$ 43.83 | 0.6 % | $ 144 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 14.26 | 3.71 % | $ 685 M | USA |
 |
Predictive Oncology
POAI
|
$ 5.95 | 0.51 % | $ 32.4 M | USA |
 |
Repligen Corporation
RGEN
|
$ 156.65 | -3.1 % | $ 8.73 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.83 | -0.31 % | $ 24.8 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 24.16 | -2.11 % | $ 1.19 B | USA |
 |
STERIS plc
STE
|
$ 251.01 | -0.59 % | $ 24.7 B | USA |
 |
Stereotaxis
STXS
|
$ 2.38 | -1.45 % | $ 192 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 125.81 | -1.13 % | $ 5.89 B | USA |
 |
Utah Medical Products
UTMD
|
$ 57.99 | 0.5 % | $ 210 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 266.92 | -2.06 % | $ 19.5 B | USA |